February 26, 2024
Chugai Pharmaceutical said on February 22 that Eli Lilly has disclosed a Form 10-K containing the economic terms for the two companies’ licensing deal for the oral obesity drug candidate orforglipron. Orforglipron is an oral non-peptidic GLP-1 receptor agonist originated...read more